MAGEA1 and hepatocellular carcinoma: Another completed phase I/II clinical trial conducted by Tada et al. evaluated the safety and efficacy of a mature-DC vaccine co-pulsed with AFP, MAGE-1, and GPC-3 proteins that was combined with TACE in treating five patients with primary HCC [45].